TEVA SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 29, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 29, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 30, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Teva Reports Q3 2026 Results, Delivers 33% Growth in Key Innovative Brands, and Raises 2026 Outlook

Nov 3, 2026

8-K

Teva Pharmaceutical Industries Ltd. Appoints Dr. David J. Brailer to its Board of Directors

Oct 29, 2026

8-K

Teva Issues €1.5 Billion and $3.2 Billion in Senior Notes to Fund Existing Note Redemptions

Sep 16, 2026

8-K

Teva Pharmaceutical Industries Ltd. Transitions Trading from ADSs to Ordinary Shares on the New York Stock Exchange

Sep 14, 2026

8-K

Teva Announces Successful Pricing of $4.9 Billion Equivalent Senior Notes

Sep 11, 2026

8-K

Teva Pharmaceutical Recasts Segment Reporting Under "Pivot to Growth" Strategy

Sep 3, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Sep 11, 2026

424B5

PENDING FIXED PRICE OFFERING

Sep 8, 2026

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

May 22, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

May 19, 2025

424B5

$2,490,000,000 (equivalent)

Mar 3, 2023

424B5

$2,060,000,000 (equivalent)

Feb 27, 2023

Registrations

TYPE

HEADLINE

FILED AT

8-A12B/A

Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]

Sep 14, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Sep 10, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Sep 10, 2026

F-6 POS

Form F-6 POS - Post-effective amendments for immediately effective filing

Jul 29, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

May 20, 2025

S-3ASR

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Feb 7, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 31, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 31, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 9, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 9, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 16, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 16, 2024

Ownerships

TYPE

HEADLINE

FILED AT

144

NEWForm 144 - Report of proposed sale of securities

Nov 9, 2026

Sabag Mark (Reporting)

Nov 6, 2026

Bergwerk Dov (Reporting)

Nov 6, 2026

144

Form 144 - Report of proposed sale of securities

Nov 5, 2026

144

Form 144 - Report of proposed sale of securities

Nov 4, 2026

SCHEDULE 13G/A

Harel Insurance Investments & Financial Services Ltd. (Filed by)

Nov 2, 2026

Other

TYPE

HEADLINE

FILED AT

Form SD - Specialized disclosure report

Jun 2, 2025

LETTER

Form UPLOAD - SEC-generated letter

Apr 28, 2025

CORRESP

Form CORRESP - Correspondence

Apr 14, 2025

LETTER

Form UPLOAD - SEC-generated letter

Apr 7, 2025

Form SD - Specialized disclosure report

May 30, 2024

LETTER

Form UPLOAD - SEC-generated letter

Apr 17, 2024

Teva Pharmaceutical Industries Limited TEVA · SEC Filings